Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03907826 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

StatusRecruiting
PhasePhase 3
Started2020-03-01
View on ClinicalTrials.gov ↗

Amendment history

2026-05-06
Study Status, Contacts/Locations v11
Primary completion date2025-12→2026-12
2025-01-25
Study Status v10
Primary completion date2024-12→2025-12
Completion date2027-12→2028-12
2024-03-14
Study Status v9
Re-verified, no change to tracked fields
2023-01-29
Study Status v8
Primary completion date2022-12→2024-12
Completion date2024-07→2027-12
2021-12-15
Study Identification, Study Status, Study Description, Conditions, Arms and Interventions v7
InterventionsIMRT (Radiation), PD-1 blocking antibody (Drug)→GP (Drug), IMRT (Radiation), PD-1 blocking antibody (Drug)
Study title-8 characters
Programmed Death-1 (PD-1) Antibody Combined With IMRTChemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Show 6 earlier versions
2021-08-08
Study Status v6
Primary completion date2021-11→2022-12
2020-03-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2019-11→confirmed 2020-03-01
Study sites1→12
2019-10-09
Study Status v4
Primary completion date2021-07→2021-11
Start date2019-07→2019-11
2019-06-11
Study Status, Outcome Measures v3
Secondary endpoints4 entries, revised
AdverseRate effectsof patients with acute toxicities
2019-06-10
Study Status v2
Primary completion date2021-05→2021-07
Completion date2024-05→2024-07
Start date2019-05→2019-07
2019-04-11
Study Status, Outcome Measures v1
Secondary endpoints5 to 4 entries
Short-term effects Quality of life: EQ-5D-5LEuroQoL 5 dimension
2019-04-08
Original filing
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Trial Details
NCT Number NCT03907826
Lead Sponsor Sun Yat-sen University
Conditions Recurrent Nasopharyngeal Carcinoma
Enrollment 212 participants
Start Date 2020-03-01
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-07